ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
Rhea-AI Summary
ProKidney Corp (Nasdaq: PROK), a late clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD), has announced its participation in two major healthcare conferences this December. The company will join the Evercore HealthCONx Conference on December 3, 2024, featuring a fireside chat at 8:45am ET with a live webcast available. Additionally, ProKidney will participate in the Citi Global Healthcare Conference on December 4, 2024, conducting one-on-one meetings.
The Evercore fireside chat webcast will be accessible through ProKidney's website investor relations section. Interested investors can arrange meetings through their Evercore and Citi representatives.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PROK gained 2.73%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December:
| Evercore HealthCONx Conference | |
| Date: | December 3, 2024 |
| Time: | 8:45am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
| Citi Global Healthcare Conference | |
| Date: | December 4, 2024 |
| Format: | One-on-one meetings |
The live webcast for the Evercore fireside chat will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should contact their Evercore and/or Citi representatives.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When is ProKidney (PROK) presenting at the Evercore HealthCONx Conference 2024?
What conferences is ProKidney (PROK) attending in December 2024?
How can investors access ProKidney's (PROK) Evercore HealthCONx Conference presentation?
What is the format of ProKidney's (PROK) participation at the Citi Global Healthcare Conference?
